Iloprost- and isoproterenol-induced increases in cAMP are regulated by different phosphodiesterases in erythrocytes of both rabbits and humans

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 296, Issue 5, 2009, Pages

  Adderley, Shaquria P ^a   Dufaux, Eileen A ^a   Sridharan, Meera ^a   Bowles, Elizabeth A ^a   Hanson, Madelyn S ^a   Stephenson, Alan H ^a   Ellsworth, Mary L ^a   Sprague, Randy S ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

adrenergic receptors; Adenosine 3 , 5 cyclic monophosphate; Adenosine 5 trisphophate; Red blood cell; Rolipram

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADENYLATE CYCLASE; CYCLIC AMP; ERYTHRO 9 (2 HYDROXY 3 NONYL1)ADENINE; ILOPROST; ISOPRENALINE; PHOSPHODIESTERASE; ROLIPRAM; UNCLASSIFIED DRUG; VINPOCETINE;

ANIMAL CELL; ARTICLE; CELL LEVEL; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME SYNTHESIS; ERYTHROCYTE MEMBRANE; EXPERIMENTAL RABBIT; HUMAN; HUMAN CELL; HYDROLYSIS; INCUBATION TIME; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; ADENOSINE TRIPHOSPHATE; ADRENERGIC BETA-AGONISTS; ANIMALS; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 2; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; ERYTHROCYTE MEMBRANE; ERYTHROCYTES; HUMANS; ILOPROST; ISOPROTERENOL; PHOSPHODIESTERASE INHIBITORS; RABBITS; SIGNAL TRANSDUCTION; SPECIES SPECIFICITY; UP-REGULATION;

EID: 66149122535     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01226.2008     Document Type: Article

References (47)

1. Babu CR, Azhar S, Krishna Murti CR. Loss of epinephrine stimulated synthesis of cyclic adenosine 3′:5′ monophosphate during maturation of rabbit and human reticulocytes. Med Biol 53: 148-155, 1975.
2. Baillie GS, Scott JD, Houslay MD. Compartmentalisation of phosphodiesterases and protein kinase A: opposites attract. FEBS Lett 579: 3264-3270, 2005.
3. Beltman J, Becker DE, Butt E, Jensen GS, Rybalkin SD, Jastorff B, Beavo JA. Characterization of cyclic nucleotide phosphodiesterases with cyclic GMP analogs: topology of the catalytic domains. Mol Pharmacol 47: 330-339, 1995.
4. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58: 488-520, 2006.
5. Bergfeld GR, Forrester T. Release of ATP from human erythrocytes in response to a brief period of hypoxia and hypercapnia. Cardiovasc Res 26: 40-47, 1992.
6. Butt E, Beltman J, Becker DE, Jensen GS, Rybalkin SD, Jastorff B, Beavo JA. Characterization of cyclic nucleotide phosphodiesterases with cyclic AMP analogs: topology of the catalytic sites and comparison with other cyclic AMP-binding proteins. Mol Pharmacol 47: 340-347, 1995.
7. Daaka Y, Luttrell LM, Lefkowitz RJ. Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature 390: 88-91, 1997. (Pubitemid 27494762)
8. 2 adrenoceptor knockout mice. Mol Pharmacol 60: 577-583, 2001.
9. Dickinson NT, Jang EK, Haslam RJ. Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: effects on platelet aggregation. Biochem J 323: 371-377, 1997.
10. Ellsworth ML. Red blood cell-derived ATP as a regulator of skeletal muscle perfusion. Med Sci Sports Exerc 36: 35-41, 2004.
11. Fimia GM, Sassone-Corsi P. Cyclic AMP signaling. J Cell Sci 114: 1971-1972, 2001.
12. Fujitani K, Kambayashi J, Murata K, Yano Y, Shinozaki K, Yukawa M, Sakon M, Murata T, Kawasaki T, Shiba E, Mori T. Clinical evaluation on combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol. Pharmacol Res 31: 121-125, 1995.
13. Hanson MS, Stephenson AH, Bowles EA, Sridharan M, Adderley S, Sprague RS. Phosphodiesterase 3 is present in rabbit and human erythrocytes and its inhibition potentiates iloprost-induced increases in cAMP. Am J Physiol Heart Circ Physiol 295: H786-H793, 2008.
14. Houslay MD, Adams DR. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 370: 1-18, 2003.
15. Lefkowitz RJ, Pierce KL, Luttrell LM. Dancing with different partners: protein kinase A phosphorylation of seven membrane-spanning receptors regulates their G protein-coupling specificity. Mol Pharmacol 62: 971-974, 2002.
16. Lerner A, Epstein PM. Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies. Biochem J 393: 21-41, 2006. (Pubitemid 43049299)
17. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 109: 366-398, 2006. (Pubitemid 43132818)
18. Manganiello VC, Degerman E. Cyclic nucleotide phosphodiesterases (PDEs): diverse regulators of cyclic nucleotide signals and inviting molecular targets for novel therapeutic agents. Thromb Haemost 82: 407-411, 1999.
19. Manns JM, Brenna KJ, Colman RW, Sheth SB. Differential regulation of human platelet responses by cGMP inhibited and stimulated cAMP phosphodiesterases. Thromb Haemost 87: 873-879, 2002.
20. Maurice DH, Haslam RJ. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol 37: 671-681, 1990.
21. Maurice DH, Palmer D, Tilley DG, Dunkerley HA, Netherton SJ, Raymond DR, Elbatarny HS, Jimmo SL. Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol Pharmacol 64: 533-546, 2003. (Pubitemid 37048555)
22. Mongillo M, Tocchetti CG, Terrin A, Lissandron V, Cheung YF, Dostmann WR, Pozzan T, Kass DA, Paolocci N, Houslay MD, Zaccolo M. Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway. Circ Res 98: 226-234, 2006. (Pubitemid 43755354)
23. Mongillo M, Zaccolo M. A complex phosphodiesterase system controls beta-adrenoceptor signalling in cardiomyocytes. Biochem Soc Trans 34: 510-511, 2006. (Pubitemid 44230749)
24. i is involved in a signal transduction pathway for ATP release from erythrocytes. Am J Physiol Heart Circ Physiol 286: H940-H945, 2004.
25. s results in ATP release from erythrocytes. Med Sci Monit 7: 669-674, 2001.
26. Perry SJ, Baillie GS, Kohout TA, McPhee I, Magiera MM, Ang KL, Miller WE, McLean AJ, Conti M, Houslay MD, Lefkowitz RJ. Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins. Science 298: 834-836, 2002. (Pubitemid 35231537)
27. 2+, calmodulin-dependent cyclic nucleotide phosphodiesterase which is involved in the hydrolysis of cGMP. Methods Find Exp Clin Pharmacol 20: 387-393, 1998.
28. Phillips PG, Long L, Wilkins MR, Morrell NW. cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling. Am J Physiol Lung Cell Mol Physiol 288: L103-L115, 2005. (Pubitemid 40023892)
29. Rich TC, Xin W, Mehats C, Hassell KA, Piggott LA, Le X, Karpen JW, Conti M. Cellular mechanisms underlying prostaglandin-induced transient cAMP signals near the plasma membrane of HEK-293 cells. Am J Physiol Cell Physiol 292: C319-C331, 2007. (Pubitemid 46115141)
30. Sadhu K, Hensley K, Florio VA, Wolda SL. Differential expression of the cyclic GMP-stimulated phosphodiesterase PDE2A in human venous and capillary endothelial cells. J Histochem Cytochem 47: 895-906, 1999. (Pubitemid 29310081)
31. Sager G. Receptor binding sites for beta-adrenergic ligands on human erythrocytes. Biochem Pharmacol 31: 99-104, 1982. (Pubitemid 12198269)
32. Schermuly RT, Roehl A, Weissmann N, Ghofrani HA, Schudt C, Tenor H, Grimminger F, Seeger W, Walmrath D. Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange. J Pharmacol Exp Ther 292: 512-520, 2000. (Pubitemid 30067413)
33. Shakur Y, Fong M, Hensley J, Cone J, Movsesian MA, Kambayashi J, Yoshitake M, Liu Y. Comparison of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heart. Cardiovasc Drugs Ther 16: 417-427, 2002. (Pubitemid 36255742)
34. Shih M, Lin F, Scott JD, Wang HY, Malbon CC. Dynamic complexes of beta2-adrenergic receptors with protein kinases and phosphatases and the role of gravin. J Biol Chem 274: 1588-1595, 1999. (Pubitemid 129507751)
35. i. Pharmacol Rep 57: 222-228, 2005.
36. Sprague RS, Bowles EA, Hanson MS, DuFaux EA, Sridharan M, Adderley S, Ellsworth ML, Stephenson AH. Prostacyclin analogs stimulate receptor-mediated cAMP synthesis and ATP release from rabbit and human erythrocytes. Microcirculation 15: 461-471, 2008.
37. Sprague RS, Ellsworth ML, Stephenson AH, Kleinhenz ME, Lonigro AJ. Deformation-induced ATP release from red blood cells requires CFTR activity. Am J Physiol Heart Circ Physiol 275: H1726-H1732, 1998.
38. Sprague RS, Ellsworth ML, Stephenson AH, Lonigro AJ. ATP: the red blood cell link to NO and local control of the pulmonary circulation. Am J Physiol Heart Circ Physiol 271: H2717-H2722, 1996.
39. Sprague RS, Ellsworth ML, Stephenson AH, Lonigro AJ. Participation of cAMP in a signal-transduction pathway relating erythrocyte deformation to ATP release. Am J Physiol Cell Physiol 281: C1158-C1164, 2001.
40. Steinberg SF, Brunton LL. Compartmentation of G protein-coupled signaling pathways in cardiac myocytes. Annu Rev Pharmacol Toxicol 41: 751-773, 2001.
41. Strehler BL. Bioluminescence assay: principles and practice. Methods Biochem Anal 16: 99-181, 1968.
42. Tao J, Wang HY, Malbon CC. Protein kinase A regulates AKAP250 (gravin) scaffold binding to the beta2-adrenergic receptor. EMBO J 22: 6419-6429, 2003. (Pubitemid 38009590)
43. Thompson PE, Manganiello V, Degerman E. Re-discovering PDE3 inhibitors - new opportunities for a long neglected target. Curr Top Med Chem 7: 421-436, 2007. (Pubitemid 46358654)
44. 2) by human erythrocytes. Br J Haematol 54: 43-52, 1983.
45. Willoughby D, Wong W, Schaack J, Scott JD, Cooper DM. An anchored PKA and PDE4 complex regulates subplasmalemmal cAMP dynamics. EMBO J 25: 2051-2061, 2006. (Pubitemid 43756222)
46. Xiang Y, Naro F, Zoudilova M, Jin SL, Conti M, Kobilka B. Phosphodiesterase 4D is required for beta2 adrenoceptor subtype-specific signaling in cardiac myocytes. Proc Natl Acad Sci USA 102: 909-914, 2005. (Pubitemid 40282764)
47. Zaccolo M, Movsesian MA. cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology. Circ Res 100: 1569-1578, 2007. (Pubitemid 46897260)